跳至主要内容
临床试验/NCT00384904
NCT00384904已完成4 期

Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine With or Without Tenofovir on the Pharmacokinetics of Atazanavir When Given With Ritonavir in HIV-Infected Subjects

Bristol-Myers Squibb3 个研究点 分布在 2 个国家目标入组 40 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
40
试验地点
3
主要终点
Atazanavir plasma drug concentrations

研究概览

简要总结

The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV-infected male and female subjects between the ages of 18 to 65 years old with a BMI 18 to 35 kg/m²
  • Prior to enrollment subjects must be currently receiving Atazanavir/Ritonavir plus at least 2 NRTIs, must have plasma HIV RNA <400 copies/mL and have CD4 count >200 cells/mm³

排除标准

  • 未提供

研究组 & 干预措施

A1

No Intervention

干预措施: Atazanavir/Ritonavir (Drug)

A2

Experimental

干预措施: Atazanavir/Ritonavir + Famotidine (Drug)

A3

Experimental

干预措施: Atazanavir/Ritonavir + Famotidine (Drug)

B1

No Intervention

干预措施: Atazanavir/Ritonavir (Drug)

B2

Experimental

干预措施: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine (Drug)

B3

Experimental

干预措施: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine (Drug)

结局指标

主要结局

Atazanavir plasma drug concentrations

时间窗: on days 10, 11, 17, 18, 24 and 25

次要结局

  • Ritonavir plasma drug concentrations(on days 10, 11, 17, 18, 24 and 25)
  • Safety measures: Physical examinations
  • ECGs(entry and discharge)
  • laboratory tests including, liver and renal function(entry, discharge and days 11, 18)
  • CD4 count(discharge)
  • HIV viral load(entry and discharge)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (3)

Loading locations...

相似试验